Patients with liver disease have increased plasma concentrations of the endogenous opioid peptides methionine enkephalin and leucine enkephalin. As an initial investigation to determine whether opioid peptides contribute to any of the clinical manifestations of hepatic disease nalmefene, a specific opioid antagonist devoid of agonist activity, was given to 11 patients with cirrhosis. They all experienced a severe opioid withdrawal reaction on starting the drug. In the nine patients with primary biliary cirrhosis pruritus was greatly alleviated, fatigue seemed to improve, and plasma bilirubin concentration, which had been rising, showed a modest fall in all except one patient.
Introduction
Opioid peptides are the naturally occurring counterparts of opiate drugs. More than 10 of these peptides have been identified.' They have multiple actions, which are exerted via at least three classes of receptors: t, 6 , and x.' Knowledge of the metabolism of these peptides, particularly at sites outside the central nervous system, is rudimentary. The plasma concentrations of the pentapeptides methionine enkephalin and leucine enkephalin are raised appreciably in patients with liver disease, and the increase is proportional to the severity of the disease.2-9 In contrast the plasma concentration of the much larger opioid peptide, 13 endorphin, is not increased in cirrhosis.6
As an initial investigation to determine whether increased activity of opioid peptides contributes to some of the clinical manifestations of liver disease we gave nalmefene (IVAX Laboratories, Miami, Florida), a specific opioid antagonist with no agonist action,7 orally to patients with cirrhosis. Nalmefene is a more potent antagonist than naloxone at all three main types of opioid receptors. When 300 mg nalmefene was given orally to healthy people it produced only occasional, minor side effects.'
Patients and methods
The study was approved by the Leeds Eastern Health Authority's ethical committee. We studied 11 patients. Nine of them had primary biliary cirrhosis, with histological appearances of the liver compatible with or diagnostic of this disease, and all nine had mitochondrial antibodies. One patient had cryptogenic cirrhosis, and one had alcoholic cirrhosis. This last patient had abstained from alcohol for 17 months. The table gives further baseline data on the patients.
In an attempt to perform a placebo controlled, randomised, double blind crossover trial we gave nalmefene or placebo to five of the patients on an outpatient basis. Three of them took the placebo for two weeks without any change in their symptoms or results of standard liver function tests. However, the two patients given nalmefene, in the lowest available dose of 5 mg, experienced a florid reaction after the first dose, which took three days to subside. They were unwilling to take further doses as outpatients, and consequently the trial proceeded on an inpatient, unblinded basis.
To try to minimise the reaction produced by nalmefene the 11 patients were given clonidine, a drug that ameliorates the symptoms of withdrawal of opiates in heroin addicts.9'" The dose of nalmefene was gradually increased over seven to 10 days from 5 6 and was stopped on day 7. Pulse rate and arterial pressure were monitored every hour for the first 12 hours on day 1 and every four hours thereafter.
All nine patients with primary biliary cirrhosis had pruritus. Four of them found that their itching was only partially alleviated by cholestyramine, and the remaining five were unable to take this drug because it worsened their steatorrhoea. To assess whether nalmefene was beneficial in alleviating these patients' itching any antipruritic drugs were stopped three weeks before the study. Pruritus was measured daily for two weeks before the study and then for two weeks at one, three, and six months; patients scored their pruritus on a visual analogue scale consisting of a 10 cm line ranging from "no itching" to "very itchy." Fatigue was assessed similarly, with a 10 cm scale ranging from "no energy" to "plenty of energy." Plasma bilirubin and albumin concentrations and alanine aminotransferase and alkaline phosphatase activities were measured twice immediately before nalmefene was started and again at one, three, and six months. The nine patients with primary biliary cirrhosis had had all these measurements taken a median of six months (range five to seven months) before the study. Splcnorenal shunt, hepatic encephalopathy BMJ VOLUME 297
Data are expressed as medians with ranges. The significance of differences was determined by Wilcoxon's signed rank sum test.
Results
All the patients experienced a considerable reaction, which began within an hour of the first doses of the two drugs. The cerebral effects were invariably unpleasant and sometimes included visual or auditory hallucinations. Two worsening ascites. It was also withdrawn in case 3 after four months because, although the patient felt better when taking the drug, her bilirubin concentration, after an initial fall, began to rise, and we could not exclude the possibility that this effect was drug induced. The remaining eight patients continued taking nalmefene for over six months.
All nine patients with itching noticed an immediate, considerable improvement in this symptom. At one month their pruritus score had fallen from 7-6 (6 4-9 8) to 0-2 (0-2-4; p<0-001), and this improvement was sustained at three months (0-2 (0-2 6); p<0-001) and six months (0 3 (0-1-8); p<0-001) (fig 1) . The patients' sense of fatigue also improved: before taking nalmefene their score was 6 -2 (1 -3-9 6), at one month it was 2-6 (10-6-9; p<0-01), at three months it was 2-4 (0-6-6-8; p<0-01), and at six months it was 2-3 (0-8-4-6; p<0-01) (fig 2) . Plasma bilirubin concentration, which had risen from 60 [tmol/l to 72 [imol/I (p<0 05)
in the six months before the patients were given nalmefene, fell to 54 [tmol/l at one month (p<O0O1), 58 (11-143) ,umol/l at threemonths (p<0 05), and 48 tmol/I at six months (p<0 02) (fig 3) . Plasma albumin concentration and alkaline phosphatase and alanine aminotransferase activities did not alter significantly at any time during the study. The three patients with the lowest baseline bilirubin concentration (cases 7-9) took nalmefene 20 mg thrice daily throughout the study. The six other patients were discharged from hospital taking nalmefene 40 mg thrice daily. Fatigue responded least well in case 2, and so the dose of nalmefene was increased at three months to 60 mg thrice daily with some apparent benefit (fig 2) .
Discussion
All the patients experienced a considerable reaction when first given nalmefene and clonidine. Clonidine, even in larger doses than those that we gave, has not been reported to produce adverse reactions in patients BMJ VOLUME 297 The alleviation of fatigue by nalmefene was less impressive. Conceivably the high plasma methionine and leucine enkephalin concentrations in patients with cirrhosis3-5 may contribute to fatigue in liver disease by a direct action on the central nervous system"-20 and this fatigue may have been alleviated by blocking opioid receptors with nalmefene. An improvement in the patients' sleep after their pruritus had been relieved may also have played a part. A placebo response cannot, however, be excluded.
Plasma bilirubin concentration had been rising in most of the patients with primary biliary cirrhosis. It fell in all of them when they started taking nalmefene and six months later remained below the baseline value in eight of them. This finding suggests that there may be a metabolic contribution to the cholestasis of primary biliary cirrhosis that is caused by increased activity of opioid peptides. One patient, however, developed deepening jaundice three months after starting nalmefene. This was probably coincidental because it continued to worsen when the drug was stopped and she had had a bilirubin concentration of over 100 [tmol/l before starting nalmefene, which often indicates rapidly progressive cholestasis.29
The patients' plasma albumin concentrations and alkaline phosphatase and alanine aminotransferase activities did not alter significantly with nalmefene. This suggests that the drug affects some of the metabolic abnormalities of liver disease without affecting the disease process itself.
The doses of nalmefene were empirical, and we did not measure the plasma concentrations of the drug. Nalmefene is eliminated predominantly in urine, partly after conjugation with glucuronic acid in the liver.30 There are no reports of hepatotoxicity caused by nalmefene.
From these results we recommend that nalmefene is started in hospital, that the initial dose is as low as possible, and, perhaps, that a higher dose of clonidine than we used is given for the first few days. Under these conditions it should be possible to determine whether opioid peptides contribute to other manifestations of liver disease23 and to evaluate the possible value of nalmefene in liver disease. 
Methods
The software system used in the study was an application of Lotus Symphony run on an IBM PC AT microcomputer. The format of the summary was based on three columns: findings, diagnoses, and management. Each column was divided into blocks of text, which were aligned horizontally and represented a single diagnosis (table I). The summary was drafted by copying the standard blocks of text from a library of entries held on a computer disk into the summary, which was then printed out. The entries on this printout were then edited by the doctor until they represented the patient's details (table II) and the changes were entered into a computer file by the secretary.
The doctor was able to check for clinical omissions and other errors as he edited the summary. This could be done while the patient was still in the ward, when any missing information was easily available. The consultant, other doctors, nurses, paramedical staff, and students caring for the patient could thus refer to the summary and comment or ask about its contents. When the patient was seen in a follow up clinic or readmitted the summary could be updated and reprinted.
ASSESSMENT OF THE SYSTEM
The new summaries were produced for all routine and emergency patients admitted to a medical department under the care of two consultant physicians over three months. The time from discharge of the patient to completion of the final summary was recorded in three different groups of patients: those admitted under the care of the two consultants who were using the new system; those admitted during the same period
